BobbyQuentinLanierMDFAAAI,FACAAI, PI

PubMed

• 5 citations
  Unanswered questions on omalizumab (Xolair) patient selection and follow-up.
  Bobby Q. Lanier, Gailen D. Marshall
  Annals of Allergy, Asthma & Immunology. 2004-02-01
• 901 citations
  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
  William W. Busse, Jonathan Corren, Bobby Q. Lanier, Margaret McAlary, Angel FowlerTaylor
  The Journal of Allergy and Clinical Immunology. 2001-08-01
• 39 citations
  Safety and tolerability of a short ragweed sublingual immunotherapy tablet
  Hendrik Nolte, Niran J. Amar, David I. Bernstein, Bobby Q. Lanier, Peter S. Creticos
  Annals of Allergy, Asthma & Immunology. 2014-07-01

Journal Articles

• Think twice before Choosing Wisely  
  Lanier B, Tex Med, 1/1/2015
• Safety and tolerability of a short ragweed sublingual immunotherapy tablet  
  Nolte H, Amar N, Bernstein DI, Lanier BQ, Creticos P, Berman G, Kaur A, Hébert J, Maloney J, Ann Allergy Asthma Immunol, 1/1/2014
• Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance  
  Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK, Allergy Asthma Proc, 1/1/2013
• Use of intranasal corticosteroids in the management of congestion and sleep disturbance in pediatric patients with allergic rhinitis  
  Lanier BQ, Clinical Pediatrics, 1/1/2008
• Pathophysiology and Progression of Nasal Septal Perforation  
  Lanier BQ, Allergy Asthma Immunology, 1/1/2007
• Baboon Syndrome Induced by Mercury-First Case Report in China  
  Lanier BQ, Contact Dermatitis, 1/1/2007
• Unanswered questions and speculations about the role of anti-immunologlobulin E in atopic and nonatopic disease  
  Lanier, Bob Q, Allergy Asthma Proceedings, 1/1/2006
• Unanswered Questions and Warnings Involving Anti-Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience  
  Lanier, Bob Q, Proceedings of Allergy Asthma and Immunology, 1/1/2005
• Unanswered questions on Omalzumab (Xolair) patient Selection and Follow-up  
  Lanier, BQ, Marshall GD Jr, Ann Allergy Asthma Immunol, 1/1/2004
• Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through t...  
  Roland PS, Kreisler LS, Reese B, Anon JB, Lanier BQ, et al, Pediatrics, 1/1/2004
• Clinical Effecacy of Olopatadine vs epinsatine ophthalmic solution in the conjunctival allergen challenge Model  
  Lanier BQ, Finegold I, D'Arienzo PA, Current Medical Research, 1/1/2004
• Omalizumab in the Treatment of Allergy and Asthma, Drug profile  
  Lanier BQ, Carr W, Therapy, 1/1/2004
• Will Anti-IgE therapt Compromise Normal Immune Functions?  
  Lanier BQ, Chang TW, Allergy & Clinical Immunology International, 1/1/2004
• Patient education doesn't work-"edu-tainment" does  
  Lanier BQ, Annals of Allergy, 1/1/2003
• Omalizumab is Effective in the Long-Term Control of Severe Allergic Asthma  
  Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor AR, Gupta N, Annals of Allergy, 1/1/2003
• Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhi...  
  Lanier BQ, Ableson MB, Berger WE, Granet DB, D'Arienzo PA, Spanlger DL, Kagi MK, Clinical Therapeutics, 1/1/2002
• Immunotherapy for asthma  
  Finegold I, Lanier BQ, Berger W, Blaiss M, Am J Respir Crit Care Med, 1/1/2002
• Anti-IgE in the real world  
  Lanier BQ, Annals of Allergy, 1/1/2002
• Increased Time to First Asthma Exacerbation Seen in Xolair Treated Patients Compared with Placebo  
  Nelson H, Fick R, Fowler-Taylor A, Ashby M, Busse W, Chervinsky P, Lanier BQ, Gupta N, Corren J, Rohane P, Ann. Allergy Asthma Immunol, 1/1/2001
• Effect of Severity of Disease on the Efficacy of Xolair-Results from Two Double-Blind, Placebo-Controlled Studies  
  Lanier BQ, Fowler-Taylor A, gupta W, McAlary M, Corren J, Matz J, Townley R, Fick R, Rohane P, Ann. Allergy Asthma Immunol, 1/1/2001
• Long-term Safety and Tolerability of Xolair-A Double Blind, Placebo-Controlled Study  
  Berger W, Nayak A, Fowler-Taylor A, Chervinsky P, Busse W, Lanier BQ, Corren J, Gupta N, Rohane P, Fick R, Ann. Allergy Asthma Immunol, 1/1/2001
• Olopatadine Ophthalmic Solution Adjunctive to Loratadine Compared to Loratadine Alone in Patients With Active Seasonal Allergic Conjunctivitis Symptoms  
  Lanier BQ, Gross R D, Marks B, Cockrum PC, Juniper EF, Annals of Allergy, Asthma, and Immunology, 1/1/2001
• No Prescription Needed-No Doctor Either  
  Lanier BQ, Annals of Allergy, Asthma & Immunology, 1/1/2001
• Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma  
  Busse W, Coren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N, Omalizumab, J Allergy Clin Immunol, 1/1/2001
• When the whole is more than the sum of it's parts  
  Lanier BQ, Annals of Allergy, Asthma, and Immunology, 1/1/2001
• Join now to see all

Books/Book Chapters

• "Allergy and Imunology" 
  Chapter: Anti-IgE pathophysiology and applications. 
  Lanier BQEditors: Lieberman and Anderson.2006
• "Atlas of Allergy" 
  Chapter: Anti-IgE 
  Lanier BQEditors: Blaiss, Liberman.2005

Abstracts/Posters

• Long-term safety and efficacy of QMF149, a once-daily, fixed-dose combination of indacaterol and mometasone furoate, in patients with persistent asthma.
  Bob Lanier, David Pearlman, Thomas Casale, Richard Beasley, Allen Moton, Han-Joo Kim, Bettina Hederer, ATS, 1/1/2012
• "The Effect of Bepotastine Besilate Ophthalmic Solution 1.5% on Prick Skin Test Reactivity measured with Histamine Controls"
  Lanier BQ Jones,D. Marks, B, AAAAI, 1/1/2011
• "Number needed to treat to prevent one exacerbation per year with omalizumab in children with inadequately controlled allergic (IgE-mediated) asthma"
  Lanier BQ, ERS, 1/1/2010
• Is there a role for Anti-IgE I the treatment of asthma in developing countries.
  Lanier BQ, AAPCI, 1/1/2010
• Rhinitis, Ocular disorders and Aerobiology.
  Lanier BQ, Session "A", ACAAI Meeting, 1/1/2009
• Efficacy and Safety of Omalizumab Added to Optimize Asthma Care in Children.
  Lanier BQ, European Respiratory Association, 1/1/2008
• "Safety and Efficacy of Olepatidine .6% Nasal spral in Perienial allergic rhinitis"
  Lanier BQ, AAAAI Annual Meeting 2006, Miami, FL, 1/1/2006
• Once-daily treatment with ciclesonide is effective and well tolerated in children with persistent asthma.
  G.Shapiro, G. Bensch R. Lanier, L. Sher M. Lloyd, S. Kundu, J. Williams, D. Banerji, Annual Meeting AAAAI, San Antonio, TX, 1/1/2005
• Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma.
  Lanier BQ, Casale TB, AAAI Annual Meeting, 1/1/2005
• Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma.
  Lanier BQ, Miller D, ATS Meeting, 1/1/2005
• Safety Of Fexofenadine In Pre-School Children With Allergic Rhinitis.
  Lanier BQ, Hampel F, Kittner B, Varghese ST, American Academy of Pediatrics, 2005 National Conference and Exhibition, Washington, DC, 1/1/2005
• "IgE does not protect against anaphylaxis with SIT"
  Lanier BQ, ACAAI Annual Meeting 2005, Anaheim, CA, 1/1/2005
• "IgE does not consistently rise with anti-IgE therapy"
  Lanier BQ, ACAAI Annual Meeting 2005, Anaheim, CA, 1/1/2005
• Anaphylaxis with SIT while being treated with Xolair.
  Lanier BQ, European Academy of Allergology and Clinical Immunology, Munich, 1/1/2005
• New Beclomethasone Diporionate Extrafine Aerosol is Effective Pediatric Asthma Therapy.
  Weinstein SF(a), Welch MJ, Lanier BQ, Nayak A, Stampone P, 58th Annual Meeting of the American Academy of Allergy Asthma and Immunology, NY, 1/1/2002
• Omalizumab Significantly Increases Time to First Asthma Exacerbation Compared with Placebo.
  Tillinghast J(a), Lanier BQ, Busse W, Chervinsky P, Ashby M, Fowler-Taylor A, Fick R, Gupta N, XXth Congress of the European Academy of Allenology and Clinical Immunology, Berlin, Germany, 1/9/2001
• Evidence of the Long-term Safety and Tolerability of Omalizumab from a Large Phase III Study.
  Lumry W(a), Berger W, Corren J, Lanier BQ, Busse W, Chervinsky P, Nayak A , Fowler-Taylor A, Fick R, Gupta N, XXth Congress of the European Academy of Allenology and Clinical Immunology, Berlin, Germany, 1/9/2001
• Omalizumab Improves Asthma-specific Quality Of Life (QoL): An Analysis Of Data From 1071 Patients.
  Busse W, Corren J, Lanier BQ, Everhard F, Surrey K, Kirchdorfer L, AAAAI, 1/1/2001
• Multi-media intervention in numerous emergency room admissions.
  Lanier,BQ, American College of Allergy, Asthma, and Clinical Immunology, 1/1/1998
• Triamcinolone Acetonide Aqueous Nasal Spray Does Not Alter Adrenocortical Function in Children With Allergic Rhinitis.
  A. Nayak, M.D., G. Feiss, M.S., J.A. Furst, B.S., B. Simpson, B.S., J.A. Smith, M.D., Easton, P.A., American Academy of Allergy Asthma and Immunology Annual Meeting, New Orleans, LA, 1/1/1996
• The Effect of Asthma Support Groups on Patient Behavior.
  Lanier, BQ, Sanders, N, American College of Allergy, Asthma, and Clinical Immunology, 1/1/1995
• Plasma Cell Antigen on the Surface of Lymphocytes in Immunodeficient Patients.
  Lanier, B.Q., Goldman, A.S., and Harris, N.A., Annual Meeting of the Reticuloendothelial Society, 1/1/1974
• Join now to see all

Lectures

• "Development of Omalizumab" 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Use of Omalizumab in Severe Allergic Asthma" 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Considerations of cost effectiveness of Xolair in Severe Allergic Asthma in developing countries." 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Omalizumab in children" 
  Italy - 1/1/2014
• "Omalzumab in children: cost effectiveness" 
  1/1/2013
• Join now to see all

Other

• Urban Eye Allergy Syndrome: A New Clinical Entity? 
  Lanier BQ, Current Medical Residency Opinion
  1/1/2008
• Prevalence and Impact of Nighttime Symptoms in Adults and Children with Asthma: A Survey. 
  Lanier, BQ, Nyak, A, Postgraduate Medicine v 120, number 4
  1/1/2008
• "Baboon Syndrome Contact Dermatitis" 
  Liping, W, Yin, J, Lanier B
  1/1/2007
• "Allergy-On The Rise and in the News" 
  Lanier BQ, Refractive Eye Care, V10 Number 2
  1/1/2006
• Analysis of the Efficacy of Technical Presentations As a Means of Sharing Data and Modifying Behavior of Professionals. 
  Lanier, BQ, Xolair Source
  1/1/2004
• "Surviving a Hospital Stay" 
  Lanier BQ, Oprah
  1/1/1999
• "Allergies-fact and myth" 
  Lanier BQ (Talent), Schering Cable Television Half Hour
  1/1/1995
• "Interactive Cases in Asthma" (CD-ROM) 
  Lanier BQ
  1/1/1995
• "Allergies-how to survive" 
  Lanier BQ (Talent), Schering Cable Television Half Hour
  1/1/1995
• "Medical Talk Etc..." 
  Lanier BQ (Talent), KCBI Radio (weekly medical talk show)
  1/1/1993
• "Good news about heart attack treatment" (30 minute broadcast documentary) 
  Lanier BQ (Talent, Producer, Writer)
  1/1/1990
• "Apathy" 
  Lanier, B.Q., Medical Portfolio
  1/1/1989
• A Matter of Opinion "A National Disgrace" 
  Lanier, B.Q., Tarrant County Physician
  1/1/1989
• Malpractice and Lawyers" 
  Lanier, B.Q., Medical Portfolio, Volume 7, No. 1
  1/1/1988
• "Doctors and Unions" 
  Lanier, B.Q., Medical Portfolio Volume 8, No. 2
  1/1/1988
• "Homeless" 
  Lanier, B.Q., Cortlandt Group
  1/1/1988
• "The New Charlatans" 
  Lanier, B.Q., RTNDA Communicator
  1/1/1987
• "Lawyer Bashing" 
  Lanier, B.Q., Medical Portfolio, Vol. 7, No. 3
  1/1/1987
• "Malpractice Prevention" 
  Lanier, B.Q., Medical Portfolio Volume 6, No. 3
  1/1/1987
• A Matter of Opinion "Affluenza" and the Millitant Patient Syndrome. 
  Lanier, B.Q., Tarrant County Physician
  1/1/1986
• A Matter of Opinion "Where Did We Go Wrong?" 
  Lanier, B.Q., Tarrant County Physician
  1/1/1985
• "Get to Know Your Patients Before You Meet Them" 
  Lanier, B.Q., Medical Economics, Pg. 121-122
  1/1/1985
• "Media Polls and HMO's" 
  Lanier, B.Q., Medical Portfolio, Vol. 6, No. 1
  1/1/1985
• "The Fate of Private Practice" 
  Lanier BQ, Nightline Guest (ABC)
  1/1/1985
• "Hospitals and Ambulatory Medicine" 
  Lanier, B.Q., Medical Portfolio, Vol. 5, No. 3
  1/1/1984
• Join now to see all